References
-
Plaintiff’s motion for summary judgment. Merck & Co., Inc., v. Xavier Becerra et al. US District Court for the District of Columbia (11 July 2023).
-
Duehren, A., Wise, L. & Rubin, R. Democrats reach deal on lowering prescription drug prices. Wall Street Journal (2 November 2021).
-
Pharmaceutical Research and Manufacturers of America. ICYMI: a Patient, Physician, Biotech Investor and Industry Leaders Warn About the Dangers of Government Price Setting Bill https://catalyst.phrma.org/icymi-a-patient-physician-biotech-investor-and-industry-leaders-warn-about-the-dangers-of-government-price-setting-bill (2022).
-
Biotechnology Innovation Organization. New Drug Pricing Bill Could Propel Us Light Years Back into the Dark Ages of Biomedical Research https://www.bio.org/press-release/new-drug-pricing-deal-could-propel-us-light-years-back-dark-ages-biomedical-research (2022).
-
Kolchinsky, P. et al. Healthcare Investors Make a Case for a Simple Fix: Parity of ‘Negotiation’ for All Drugs at 13 Years https://nopatientleftbehind.docsend.com/view/e4cg7sgj6js5qenr (2022).
-
Buxbaum, J., Chernew, M., Fendrick, A. & Cutler, D. Contributions of public health, pharmaceuticals, and other medical care to US life expectancy changes, 1990–2015. Health Aff. 39, 1546–1556 (2020).
-
Cutlerc, D., Rosen, A. & Vijan, S. The value of medical spending in the United States, 1960–2000. N. Engl. J. Med. 355, 920–927 (2006).
-
United States Government Accountability Office. Drug Industry: Profits, Research and Development Spending, and Merger and Acquisition Deals. GAO-18-40 https://www.gao.gov/products/gao-18-40 (2017).
-
Dusetzina, S., Huskamp, H., Qin, X. & Keating, N. Prescription drug spending in fee-for-service Medicare, 2008–2019. JAMA 328, 1515–1522 (2022).
-
Congressional Budget Office. Estimated Budgetary Effects of Public Law 117-169 https://www.cbo.gov/system/files/2022-09/PL117-169_9-7-22.pdf (2022).
-
Congressional Budget Office. CBO’s Model of New Drug Development https://www.cbo.gov/publication/57450 (2022).
-
Philipson, T. & Durie, T. Issue Brief: the Impact of HR 5376 on Biopharmaceutical Innovation and Patient Health https://cpb-us-w2.wpmucdn.com/voices.uchicago.edu/dist/d/3128/files/2021/08/Issue-Brief-Drug-Pricing-in-HR-5376-11.30.pdf (2021).
-
Gassull, D., Bowen, H., & Schulthess, D. IRA’s Impact on the US Biopharma Ecosystem https://vitaltransformation.com/2023/05/iras-impact-on-the-us-biopharma-ecosystem (2023).
-
Dickson, S. & Hernandez, I. Drugs likely subject to Medicare negotiation, 2026–2028. J. Manag. Care Spec. Pharm. 29, 229–235 (2023).
-
Rome, B. et al. Simulated Medicare drug price negotiation under the Inflation Reduction Act of 2022. JAMA Health Forum 4, e225218 (2023).
-
Reitsma, M. et al. Examining opportunities to increase savings from Medicare price negotiations. JAMA Intern. Med. 183, 581–588 (2023).
-
Schuhmacher, A. et al. The significance of blockbusters in the pharmaceutical industry. Nat. Rev. Drug Discov. 22, 177–178 (2023).
-
Evaluate Pharma. World Preview 2022, Outlook to 2028: Patents and Pricing https://info.evaluate.com/rs/607-YGS-364/images/2022%20World%20Preview%20Report.pdf (2022).
-
Hernandez, I., San-Juan-Rodriguez, A., Good, C. & Gellad, W. Changes in list prices, net prices, and discounts for branded drugs in the US, 2007–2018. JAMA 323, 854–862 (2020).
-
Brown, A. The Patent Winter is Coming https://www.evaluate.com/vantage/articles/insights/other-data/patent-winter-coming (2022).
-
Dixit, R. & David, F. Market watch: trends in pharmaceutical company R&D spending: 2005–2015. Nat. Rev. Drug Discov. 16, 376 (2017).
-
Elmhirst, E. COVID Drives a Record Jump in Research Spending for Big Pharma https://www.evaluate.com/node/17806/pdf (2022).
-
Joint Committee on Taxation. Memorandum: Analysis of Large Pharmaceutical Corporation Tax Data https://www.finance.senate.gov/imo/media/doc/JCT%20-%20pharma%20tax%20data%205.4.23.pdf (2023).
-
Krieger, J., Li, X. & Thakor, R. Find and Replace: R&D Investment Following the Erosion of Existing Products Working Paper 19-058 (Harvard Business School, 2021).
-
Ringel, M. What is the right amount to spend on biopharma R&D? Nat. Rev. Drug Discov. 16, 597–598 (2017).
-
Yin, W. Market incentives and pharmaceutical innovation. J. Health Econ. 27, 1060–1077 (2008).
-
Blume-Kohout, M. & Sood, N. Market size and innovation: effects of Medicare Part D on pharmaceutical research and development. J. Public Econ. 97, 327–336 (2013).
-
Agha, L., Kim, S., & Li, D. Insurance design and pharmaceutical innovation. Am. Econ. Rev. Insights 4, 191–208 (2022).
-
Branstetter, L., Chatterjee, C., & Higgins, M. Generic Competition and the Incentives for Early-Stage Pharmaceutical Innovation Working Paper 20532 https://www.nber.org/system/files/working_papers/w20532/w20532.pdf (NBER, 2022).
-
Vogel, M., Kesselheim, A., Feldman, W. & Rome, B. Will Medicare price negotiation delay cancer-drug launches? N. Engl. J. Med. 389, 1546–1548 (2023).
-
Congressional Budget Office. How CBO Estimated the Budgetary Impact of Key Prescription Drug Provisions in the 2022 Reconciliation Act https://www.cbo.gov/system/files/2023-02/58850-IRA-Drug-Provs.pdf (2023).
-
Frank, R., McGuire, T. & Nason, I. The evolution of supply and demand in markets for generic drugs. Milbank Q. 99, 828–852 (2021).
-
Vogel, M. et al. Cost of exempting sole orphan drugs from Medicare negotiation. JAMA Intern. Med. 184, 63–69 (2024).
-
Abbott, T. & Vernon, J. The cost of US pharmaceutical price regulation: a financial simulation model of R&D decisions. Manage. Decis. Econ. 28, 293–306 (2007).
-
Kerr, W. & Nanda, R. Financing innovation. Annu. Rev. Financ. Econ. 7, 445–462 (2015).
-
Fougner, C. et al. Herding in the drug development pipeline. Nat. Rev. Drug Discov. 22, 617–618 (2023).
-
Bloom, N., Schankerman, M. & Van Reenen, J. Identifying technology spillovers and product market rivalry. Econometrica 81, 1347–1393 (2013).
-
Dranove, D., Garthwaite, C. & Hermosilla, M. Does consumer demand ‘pull’ scientifically novel drug innovation? Rand J. Econ. 53, 590–638 (2022).
-
Byrski, D., Gaessler, F. & Higgins, M. Market Size and Research: Evidence from the Pharmaceutical Industry Working Paper 28858 https://www.nber.org/system/files/working_papers/w28858/w28858.pdf (National Bureau of Economics Research, 2021).
-
Frank, R., Conti, R. & Gruber, J. International reference pricing in the context of US drug policy. J. Health Polit. Policy Law 47, 779–796 (2022).
-
Conti, R., Frank, R. & Nichols, L. How do commercial insurance plans fare under proposed prescription drug price regulation? JAMA Health Forum 2, e214242 (2021).
-
Adler, L. Cost-Shifting in Drug Pricing, or the Lack Thereof https://www.brookings.edu/articles/cost-shifting-in-drug-pricing-or-the-lack-thereof (2021).
-
Clemens, J. & Gottlieb, J. In the shadow of a giant: Medicare’s influence on private physician payments. J. Polit. Econ. 125, 1–39 (2017).
-
Dusetzina, S., Keating, N., Huskamp, H. & Mello, M. Medicare’s plan for drug-price negotiation: the importance of defining generic entry. N. Engl. J. Med. 389, 97–100 (2023).
-
Rome, B., Egilman, A. & Kesselheim, A. Trends in prescription drug launch prices, 2008–2021. JAMA 327, 2145–2147 (2022).
-
Congressional Budget Office. Re: Additional Information About Drug Price Negotiation. https://www.cbo.gov/system/files/2023-12/59792-Letter.pdf (2023).
-
Cha, M., Rifai, B. & Sarraf, P. Pharmaceutical forecasting: throwing darts? Nat. Rev. Drug Discov. 12, 737–738 (2013).
-
DiMasi, J., Grabowski, H. & Hansen, R. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20–33 (2016).
-
Wouters, O., McKee, M. & Luyten, J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA 323, 844–853 (2020).
-
Frank, R. & Zeckhauser, R. Excess Prices for Drugs in Medicare: Diagnosis and Prescription Working Paper RWP18-005 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3116330 (Harvard Kennedy School, 2018).
